RAMM Pharma

RAMM Pharma Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of RAMM Pharma (RAMM.CN) as of Oct 22, 2026 is 87.02. In the previous year, Cash Conversion Cycle (CCC) was 334.51 — a change of -73.99% (lower).

Cash Conversion Cycle

87.02

YoY

-73.99%

Last updated:

Cash Conversion Cycle (CCC) of RAMM Pharma is 2025 87.02 . Cash Conversion Cycle (CCC) of RAMM Pharma was 2024 334.51 . It decreases by -73.99% lower compared to the previous year.

The RAMM Pharma Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
102.43 CAD
Jan 1, 2019
101.36 CAD
Jan 1, 2020
186.37 CAD
Jan 1, 2021
203.14 CAD
Jan 1, 2022
394.41 CAD
Jan 1, 2023
194.47 CAD
Jan 1, 2024
334.51 CAD
Jan 1, 2025
87.02 CAD
The RAMM Pharma Cash Conversion Cycle history
YEARCash Conversion CycleYoY
87.02-73.99%
334.51+72.01%
194.47-50.69%
394.41+94.16%
203.14+9.00%
186.37+83.87%
101.36-1.05%
102.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

Cash Conversion Cycle (CCC) of RAMM Pharma is 87.02 in 2025.

Cash Conversion Cycle (CCC) of RAMM Pharma changed from 334.51 to 87.02, representing a -73.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s RAMM Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — RAMM Pharma

All Key Metrics — RAMM Pharma